Unexpected Comeback of Hydroxychloroquine 2022

If you have followed the development of early treatment protocols for COVID-19, you will be aware that for well over a year, Ivermectin was the central agent in the FLCCC protocol, for prevention and early treatment. Ivermectin is also part of the hospital level protocols.

Very early on, as discussed in this interview with Professor Varon, Hydroxychloroquine was present in the protocol, but it was dropped mid-2020. 

This non-inclusion of Hydroxychloroquine appears to have been in part due to the bad publicity that hydroxychloroquine was suffering from, as it was targeted by the mainstream media, especially in relation to the presidential campaign in the US in 2020.

Comeback of Hydroxychloroquine

This January 19, 2022; it’s therefore a bit of a surprise to see Hydroxychloroquine to re-appear in the FLCCC prevention and early treatment protocol.

The move follows the experience of several frontline doctors who found that Hydroxychloroquine is particularly useful to deal with Omicron, in combination with Ivermectin and other agents, as indicated in the protocol.

Source: https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/
So, with this move, we will expect less confusion and conflict among frontline doctors regarding the nature of the most appropriate agents to be included in early treatment protocols for COVID-19.

Hydroxychloroquine and Clinical Evidence (Updated)

As of February 2022 there have been more than 30 studies of Hydroxychloroquine for early treatment with an overall average improvement of 64% as compared to the control groups.

Hydroxychloroquine (HCQ) is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies.

Here’s a chart from c19early.com that shows that hydroxychloroquine performs better than ivermectin when given as early treatment in terms of risk reduction of dying from COVID-19:


The overall improvement for hydroxychloroquine is better than ivermectin (for early treatment); 74 % vs 44 % in terms of death rate. Importantly, hydroxychloroquine needs to be given 'early'

The difference in terms of effectiveness for hydroxychloroquine is distinctly different when given early vs late treatment (64% vs 20%), as shown in the summary chart below:


The evidence tracking on Hydroxychloroquine versus COVID-19 is available at c19hcq.com (constantly updated).

Comments

Popular posts from this blog

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (April 2022)

Dr Peter McCullough Early Treatment Protocol 2022

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments

How to Make Povidone Iodine 1% Nasal Spray

America's Frontline Doctors Early Treatment Protocol and Contact a Physician 2022

Quercetin and Zinc: Zelenko Treatment Protocol (2022)

Dr Peter McCullough: Nasal Spray and Mouth Gargle to stop COVID?

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (March 2022)

Dr Peter McCullough: Fact Check and Debunked Theories

Dr. Peter McCullough Shares the Four Pillars of COVID-19 Care with Pennsylvania Lawmakers